1
                                [T CELL LOGO]

                                                                 Exhibit 20.0

NEWS RELEASE
- ------------

Date:     FOR IMMEDIATE RELEASE/NOVEMBER 7, 1995

Contact:  Alan Tuck                                  Lori Martin
          President & Chief Executive Officer        Investor Relations
          T Cell Sciences, Inc.                      T Cell Sciences, Inc.
          (617) 433-0771                             (617) 433-3107



       T CELL SCIENCES, INC. ANNOUNCES OVER $6 MILLION PRIVATE PLACEMENT


Needham, MA, November 7, 1995 -- T Cell Sciences, Inc. (NASDAQ: TCEL) today
announced the closing of a $6.375 million private placement of 2.55 million
shares of T Cell Sciences Common Stock, $.001 par value. Several institutional
investors and private investors purchased shares of Common Stock pursuant to
stock purchase agreements. The Company has filed a registration statement with
the Securities and Exchange Commission to register the resale of the Common
Stock purchased by the investors. The Company directly placed a number of the
shares purchased and Allen & Company acted as placement agent for the other
shares.

"We are pleased we had the opportunity to raise additional capital and to
strengthen the Company's position for future growth," said Alan Tuck, President
and Chief Executive Officer. "The funds received from this financing will be
used primarily to advance the Company's complement inhibitor program, including
Phase II clinical trials in 1996. The completion of this financing plus the
additional positive announcements we expect over the next several months should
help us continue to build shareholder value."

In July of this year, T Cell completed Phase I clinical trials which indicate
soluble complement receptor 1, (product name TP10), is safe, and can inhibit
complement activation in adult patients at risk for Adult Respiratory Distress
Syndrome (ARDS). In May of this year, the Company's subsidiary T Cell
Diagnostics received FDA marketing clearance for TRAx[register mark] CD4, an
immunoassay test kit for the enumeration of CD4 T Cells, which is currently
being launched in the marketplace.

T Cell Sciences, Inc. is developing pharmaceutical products for the treatment of
inflammatory disorders and autoimmune diseases utilizing proprietary complement
inhibitor and T Cell receptor technology. T Cell Diagnostics, a wholly owned
subsidiary of T Cell Sciences, develops, manufactures and markets innovative
immune monitoring diagnostics and research products.

                                      ###


T Cell Sciences, Inc. 115 Fourth Avenue Needham, MA 02194-2725 USA 617-433-0771
- --------------------------------------------------------------------------------
                            Telefax 1-617-433-0262